Moolec Science (MLEC) Current Deferred Revenue (2024 - 2025)
Moolec Science's (MLEC) quarterly Current Deferred Revenue came in at $1260.0 in Q2 2025, down 99.97% year-on-year from $3.9 million in Q2 2024, and down 99.97% quarter-over-quarter from $3.9 million in Q2 2024.
Moolec Science (MLEC) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Moolec Science has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $1260.0 for Q2 2025.
- Current Deferred Revenue for Q2 2025 came in at $1260.0, down 99.97% year-over-year; the trailing twelve-month figure through Jun 2025 was $1260.0 (down 99.97% YoY), and the FY2025 annual result was $1260.0, down 99.97% from the prior year.
- Current Deferred Revenue came in at $1260.0 for Q2 2025 at Moolec Science, down from $3.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.9 million in Q2 2024 to a low of $1260.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,260.00 |
| Jun 30, 2024 | 3.92 Mn |